| |
|
|
|
|
|
 |
| |
|
³×¿À¹Ì³ëȰվ¾ÁÖ20mL NEOMINOPHAGEN-C INJ.20ml
|
Àü¹®ÀǾàǰ | ºñ±Þ¿©
|
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
655600141[655600140]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»öÀÇ Åõ¸íÇÑ ¾×ÀÌ µç ¾ÚÇÃÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
20ml/¾ÚÇÃ |
| ÁÖ¼ººÐÄÚµå |
327300BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
µÎµå·¯±â¤ý½ÀÁø¤ý¾Ë·¹¸£±â¼º ÇǺÎÁúȯ, ¾à¹°Áßµ¶ÀÇ º¸Á¶¿ä¹ý
¸¸¼º°£ÁúȯÀÇ °£±â´É °³¼±
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ 1ÀÏ 1ȸ 2~20§¢¸¦ Á¤¸ÆÁÖ»çÇÑ´Ù.
¸¸¼º°£Áúȯ¿¡´Â 1ȸ 40~60mL, 1ÀÏ 1ȸ Á¤¸Æ ¶Ç´Â Á¡ÀûÁ¤¸ÆÁÖ»çÇÑ´Ù. Áõ·®ÇÏ´Â °æ¿ì¿¡´Â 1ÀÏ ÃÖ´ë 100mL¸¦ ÃʰúÇÏÁö ¾Ê´Â´Ù. ¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ °ú¹ÎÁõ ȯÀÚ
2) ¾Ëµµ½ºÅ×·ÐÁõ ȯÀÚ, ±ÙÀ°º´º¯ÀÌ Àִ ȯÀÚ, ÀúÄ®·ýÇ÷Áõ ȯÀÚ(ÀúÄ®·ýÇ÷Áõ, °íÇ÷¾Ð µîÀ» ¾ÇȽÃų ¼ö ÀÖ´Ù.)
|
| ½ÅÁßÅõ¿© |
1) °í·ÉÀÚ(ÀúÄ®·ýÇ÷Áõ µîÀÇ ¹ßÇöÀ²ÀÌ ³ô´Ù.)
2) ÀÌ ¾àÀº ÇǷξÆÈ²»ê³ªÆ®·ýÀÌ ÇÔÀ¯µÇ¾î ÀÖ¾î ¾Æ³ªÇʶô½Ã¿Í °°Àº ¾Ë·¹¸£±â¸¦ ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç ÀϺΠ°¨¼ö¼º ȯÀÚ¿¡¼´Â »ý¸íÀ» À§ÇùÇÒ Á¤µµ ¶Ç´Â À̺¸´Ù ¾àÇÑ Ãµ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ÀÏ¹Ý »ç¶÷¿¡¼ÀÇ ¾ÆÈ²»ê°¨¼ö¼º¿¡ ´ëÇÑ ÃѰýÀûÀÎ ºóµµ´Â ¾Ë·ÁÁöÁö ¾Ê¾ÒÀ¸³ª ³·Àº °ÍÀ¸·Î º¸ÀÌ¸ç ¾ÆÈ²»ê°¨¼ö¼ºÀº ºñõ½ÄȯÀÚº¸´Ù õ½ÄȯÀÚ¿¡¼ ºó¹øÇÑ °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
|
| ÀÌ»ó¹ÝÀÀ |
1) ¼ï : ¼ï, ¾Æ³ªÇʶô½Ã¼º ¼ï(Ç÷¾ÐÀúÇÏ, ÀǽļҽÇ, È£Èí°ï¶õ, ½ÉÆóÁ¤Áö, È«Á¶, ¾È¸éºÎÁ¾ µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ Çϰí ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ Áï½Ã ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
2) À§¾Ëµµ½ºÅ×·ÐÁõ : Áõ·® ¶Ç´Â Àå±â¿¬¿ë¿¡ ÀÇÇÏ¿© °íµµÀÇ ÀúÄ®·ýÇ÷Áõ, ÀúÄ®·ýÇ÷ÁõÀÇ ¹ßÇöºóµµ»ó½Â, Ç÷¾Ð»ó½Â, ³ªÆ®·ý¡¤Ã¼¾×ÀÇ Àú·ù, ºÎÁ¾, üÁßÁõ°¡ µîÀÇ À§(êÊ)¾Ëµµ½ºÅ× ·ÐÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î, Ç÷ûĮ·ýÄ¡ ÃøÁ¤ µî °üÂûÀ» ÃæºÐÈ÷ Çϰí ÀÌ»óÀÌ ÀÎÁ¤ µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù. ¶ÇÇÑ ÀúÄ®·ýÇ÷ÁõÀÇ °á°ú·Î¼ ¹«·Â°¨, ±Ù·ÂÀúÇÏ µî ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ±× ¿Ü ÀÌ»ó¹ÝÀÀ : ´ÙÀ½°ú °°Àº Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ°í, Åõ¿©·®ÀÇ Áõ°¡¿¡ ÀÇÇÏ¿© Ç÷ ûĮ·ýÄ¡ÀÇ ÀúÇÏ, Ç÷¾Ð»ó½ÂÀÇ ¹ßÇöºóµµÀÇ »ó½Â°æÇâÀÌ ³ªÅ¸³´Ù.
¨ç ü¾×¡¤ÀüÇØÁú : ¶§¶§·Î Ç÷ûĮ·ýÄ¡ÀÇ ÀúÇÏ, Ç÷¾Ð»ó½Â µå¹°°Ô ºÎÁ¾ Àü½Å±Çۨ, ±Ù À°ÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¨è ±âŸ : µå¹°°Ô ¹ßÁø, ÀÌ»ó¹ÝÀÀ, µÎÅë, ¿°¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
´ÙÀ½ÀÇ ÀÌ´¢Á¦¿Í º´¿ë½Ã À̵éÀÇ ÀÌ´¢ÀÛ¿ëÀº ÀÌ ¾à¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â ±Û¸®½Ã¸®ÁøÀÇ Ä® ·ý¹è¼³ÀÛ¿ëÀ» Áõ°½ÃÄÑ, Ç÷ûĮ·ýÄ¡ÀÇ ÀúÇϰ¡ ³ªÅ¸³ª±â ½¬¿öÁ® ÀúÄ®·ýÇ÷Áõ(¹«·Â°¨, ±Ù ·ÂÀúÇÏ µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î Ç÷ûĮ·ýÄ¡ÀÇ ÃøÁ¤ µî °üÂûÀ» ÃæºÐÈ÷ Çϰí ÁÖÀÇÇÑ ´Ù. : Ä¡¾ÆÁþ°è ¹× À¯»ç °¾ÐÀÌ´¢Á¦(Æ®¸®Å¬·Î¸£¸ÞÄ¡¾ÆÁþ µî), ·çÇÁ°è ÀÌ´¢Á¦(¿¡Å¸Å©¸° »ê, Ǫ·Î¼¼¹Ìµå µî) |
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ¼ººÐÄÚµå |
M088656/±Û¸®½Å 400¹Ð¸®±×·¥ /
M246698/½Ã½ºÅ×Àο°»ê¿°¼öȹ° 22.29¹Ð¸®±×·¥ /
M050098/±Û¸®½Ã¸®Áø»ê¾Ï¸ð´½ 53¹Ð¸®±×·¥ /
|
| ÁÖ¼ººÐÄÚµå |
327300BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806556001407 |
| BIT ¾àÈ¿ºÐ·ù |
´ãÁó»êºÐºñÃËÁøÁ¦ & °£º¸È£Á¦ (Cholelitholitics & Hepatic Protectors)
|
| ATC ÄÚµå |
Liver therapy / A05BA
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
392 (ÇØµ¶Á¦ )
|
| ÀǾàǰ ¹ÙÄÚµåÁ¤º¸ |
³»¿ëº¸±â
³×¿À¹Ì³ëȰվ¾ÁÖ20¹Ð¸®¸®ÅÍ/ E01700201
Á¦Ç°±Ô°Ý: 20¹Ð¸®¸®ÅÍ/Á¦Ç°¼ö·®: 1/Á¦Çü: ¾ÚÇÃ
Æû¸ñ±âÁØÄÚµå: 200611517 /´ëÇ¥ÄÚµå: 8806556001407/Ç¥ÁØÄÚµå: 8806556001414
±¸¹ÙÄÚµå: -/ºñ°í:-
³×¿À¹Ì³ëȰվ¾ÁÖ20¹Ð¸®¸®ÅÍ/ E01700201
Á¦Ç°±Ô°Ý: 20¹Ð¸®¸®ÅÍ/Á¦Ç°¼ö·®: 30/Á¦Çü: ¾ÚÇÃ
Æû¸ñ±âÁØÄÚµå: 200611517 /´ëÇ¥ÄÚµå: 8806556001407/Ç¥ÁØÄÚµå: 8806556001421
±¸¹ÙÄÚµå: 8806111903986/ºñ°í:-
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Glycine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ In the CNS, there exist strychnine-sensitive glycine binding sites as well as strychnine-insensitive glycine binding sites. The strychnine-insensitive glycine-binding site is located on the NMDA receptor complex. The strychnine-sensitive glycine receptor complex is comprised of a chloride channel and is a member of the ligand-gated ion channel superfamily. The putative antispastic activity of supplemental glycine could be mediated by glycine's binding to strychnine-sensitive binding sites in the spinal cord. This would result in increased chloride conductance and consequent enhancement of inhibitory neurotransmission. The ability of glycine to potentiate NMDA receptor-mediated neurotransmission raised the possibility of its use in the management of neuroleptic-resistant negative symptoms in schizophrenia. Animal studies indicate that supplemental glycine protects against endotoxin-induced lethality, hypoxia-reperfusion injury after liver transplantation, and D-galactosamine-mediated liver injury. Neutrophils are thought to participate in these pathologic processes via invasion of tissue and releasing such reactive oxygen species as superoxide. In vitro studies have shown that neutrophils contain a glycine-gated chloride channel that can attenuate increases in intracellular calcium and diminsh neutrophil oxidant production. This research is ealy-stage, but suggests that supplementary glycine may turn out to be useful in processes where neutrophil infiltration contributes to toxicity, such as ARDS.
L-cysteine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Although classified as a non-essential amino acid cysteine may be essential for infants, the elderly, and individuals with certain metabolic disease or who suffer from malabsorption syndromes. Cysteine can usually be synthesized by the human body under normal physiological conditions if a sufficient quantity of methionine is available. Due to the ability of thiols to undergo redox reactions, cysteine has antioxidant properties. Cysteine's antioxidant properties are typically expressed in the tripeptide glutathione, which occurs in humans as well as other organisms. The systemic availability of oral glutathione (GSH) is negligible; so it must be biosynthesized from its constituent amino acids, cysteine, glycine, and glutamic acid. Glutamic acid and glycine are readily available in the diets of most industrialized countries, but the availability of cysteine can be the limiting substrate. Cysteine is also an important source of sulfide in human metabolism. The sulfide in iron-sulfur clusters and in nitrogenase is extracted from cysteine, which is converted to alanine in the process. In a 1994 report released by five top cigarette companies, cysteine is one of the 599 additives to cigarettes. Its use or purpose, however, is unknown, like most cigarette additives. Its inclusion in cigarettes could offer two benefits: Acting as an expectorant, since smoking increases mucus production in the lungs; and increasing the beneficial antioxidant glutathione (which is diminished in smokers).
|
| Pharmacology |
Glycine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Helps trigger the release of oxygen to the energy requiring cell-making process; Important in the manufacturing of hormones responsible for a strong immune system.
L-cysteine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Due to this ability to undergo redox reactions, cysteine has antioxidant properties. Cysteine is an important source of sulfur in human metabolism, and although it is classified as a non-essential amino acid, cysteine may be essential for infants, the elderly, and individuals with certain metabolic disease or who suffer from malabsorption syndromes. Cysteine may at some point be recognized as an essential or conditionally essential amino acid.
|
| Metabolism |
L-cysteine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Absorption |
Glycine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed from the small intestine via an active transport mechanism.
|
| Pharmacokinetics |
Aminoacetic Acid(Glycine)ÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´ë»ç : GlycineÀº ´Ü¹é, creatinine, glycocholic acid, glutathione, uric acid, heme µîÀÇ ÇÕ¼º¿¡ °ü¿©ÇÑ´Ù.
ü³»¿¡¼ÀÇ ºÐÇØ´Â ¿©·¯´Ü°è·Î ÀÌ·ç¾îÁö¸ç ÁÖµÈ °æ·Î´Â °¡¿ªÀûÀÎ »êÈÀû ºÐÇØÀÌ´Ù.
SerineÀÌ Á¤»óÀûÀÎ ºÐÇØ»ê¹°ÀÌ´Ù.
- Ç÷Àå ¹Ý°¨±â : 85ºÐ
|
| Biotransformation |
Glycine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
L-cysteine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Glycine¿¡ ´ëÇÑ Toxicity Á¤º¸ ORL-RAT LD50 7930 mg/kg, SCU-RAT LD50 5200 mg/kg, IVN-RAT LD50 2600 mg/kg, ORL-MUS LD50 4920 mg/kg; Doses of 1 gram daily are very well tolerated. Mild gastrointestinal symptoms are infrequently noted. In one study doses of 90 grams daily were also well tole.
L-cysteine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Glycine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
L-cysteine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Glycine¿¡ ´ëÇÑ Description Á¤º¸ A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [PubChem]
L-cysteine¿¡ ´ëÇÑ Description Á¤º¸ A thiol-containing non-essential amino acid that is oxidized to form cystine. [PubChem]
|
| Drug Category |
Glycine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementGlycine AgentsMicronutrientNon-Essential Amino Acids
L-cysteine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementNutritional Supplement
|
| Smiles String Canonical |
Glycine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NCC(O)=O
L-cysteine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(CS)C(O)=O
|
| Smiles String Isomeric |
Glycine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NCC(O)=O
L-cysteine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N[C@@H](CS)C(O)=O
|
| InChI Identifier |
Glycine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)/f/h4H
L-cysteine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1/f/h5H
|
| Chemical IUPAC Name |
Glycine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-aminoacetic acid
L-cysteine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2R)-2-amino-3-sulfanylpropanoic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-09-30
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|